CGK012
Product Specifications
UNSPSC Description
CKG012 is an inhibitor for Wnt/βcatenin signaling pathway. CGK012 inhibits release of HMGB1 and transcription of β-catenin, exhibits attenuating activities against cecal ligation and puncture (CLP)-induced sepsis and multiple myeloma cancer[1][2].
Target Antigen
β-catenin
Type
Reference compound
Related Pathways
Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cgk012.html
Solubility
10 mM in DMSO
Smiles
O=C(O[C@H]1CC2=CC(C=CC3=O)=C(O3)C=C2OC1(C)C)NC4CCCC4
Molecular Weight
357.40
References & Citations
[1]Park YJ, et al., Antiseptic Functions of CGK012 against HMGB1-Mediated Septic Responses. Int J Mol Sci. 2024 Mar 4;25(5):2976. |[2]Choi PJ,et al., Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation. Leuk Res. 2017 Sep;60:103-108.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-163409/CGK012-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-163409/
Clinical Information
No Development Reported
CAS Number
2044497-76-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS634869-01 0.05 mg
Vascular Endothelial Growth Factor, Human (VEGF, VEGF 121, VEGF121, VEGF A, VEGFA, VEGF-A, MGC70609, Vascular Permeability Factor, VPF)
Ask
View Details 
MBS634869-02 5x 0.05 mg
Vascular Endothelial Growth Factor, Human (VEGF, VEGF 121, VEGF121, VEGF A, VEGFA, VEGF-A, MGC70609, Vascular Permeability Factor, VPF)
Ask
View Details 
ARP64234_P050-Biotin 100 µL
RASSF2 Antibody - C-terminal region: Biotin (ARP64234_P050-Biotin)
Ask
View Details MBS7019000-01 0.02 mg
Recombinant Haemophilus influenzae Lipoprotein-releasing system transmembrane protein LolC (lolC)
Ask
View Details MBS7019000-02 0.1 mg
Recombinant Haemophilus influenzae Lipoprotein-releasing system transmembrane protein LolC (lolC)
Ask
View Details